A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B
Edward J. Gane, Yao‐Chun Hsu, Chi-Yi Chen, Shyamasundaran Kottilil et autres
0 citationsHepatology
Texas Liver Institute
San Antonio · US · healthcare
547Publications signalées
56974Citations signalées
12Thèmes principaux
Principaux domaines
Liver Disease Diagnosis and TreatmentHepatitis C virus researchHIV/AIDS drug development and treatmentLiver Disease and TransplantationLiver Diseases and ImmunityHepatitis B Virus StudiesDrug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance MechanismsHepatocellular Carcinoma Treatment and PrognosisSystemic Lupus Erythematosus ResearchLiver physiology and pathologyDiet, Metabolism, and Disease
Évolution annuelle
Publications récentes
Weight reduction–dependent/–independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH
Mazen Noureddin, Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf et autres
0 citationsHepatology
Seladelpar is associated with a sustained reduction in cholestatic markers and a consistent safety profile in patients with primary biliary cholangitis treated up to 48 months in the ongoing, open-label ASSURE study
D Pratt, E J Lawitz, C L Bowlus, S Gehring et autres
0 citationsZeitschrift für Gastroenterologie
Efficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 RESPONSE study
M J Mayo, E J Lawitz, A M Villamil, E Janczewska et autres
0 citationsZeitschrift für Gastroenterologie
Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial
J M Schattenberg, R Loomba, K V Kowdley, M Y Sheikh et autres
0 citationsZeitschrift für Gastroenterologie
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial
Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Ulus Salih Akarca et autres
0 citationsJournal of Hepatology
Liver Biopsy in Metabolic Dysfunction‐Associated Steatohepatitis Clinical Trials: Potential Pitfalls and Solutions
Eric Lawitz, Fred Poordad, ZACHARY D. GOODMAN
0 citationsLiver International
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Rohit Loomba, Jacob George, L Castera, Sven Francque et autres
1 citationThe Lancet. Gastroenterology & hepatology
Development of a Patient Journey Map for Metabolic Dysfunction–Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North America
David O. Garcia, Roberto A. Calle, Abhinav Seth, Thomas Norton et autres
0 citationsJournal of Patient Experience
P62 Seladelpar linked to sustained reduction in cholestatic markers with consistent safety profile in PBC up to 48 months in ASSURE
Arran Ludlow-Rhodes, Eric Lawitz, Christopher Bowlus, Kyung Min Kwon et autres
0 citationsE-Posters
P55 Long-term elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis (PBC)
Amandeep Phagura, Cynthia Levy, Ulus Akarca, Mario Reis Alvares-da-Silva et autres
0 citationsE-Posters
A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma
David J. Taggart, Shivani Mahajan, Maxime A. Gallant, Itai Pinkoviezky et autres
5 citationsJournal of Hepatology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.